KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Shares Outstanding (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Shares Outstanding for 16 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding changed 0.16% to $5.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.1 million, a 0.16% change, with the full-year FY2025 number at $5.1 million, changed 0.16% from a year prior.
  • Shares Outstanding was $5.1 million for Q4 2025 at Bio-Rad Laboratories, down from $25.2 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $25.2 million in Q4 2024 to a low of $5.1 million in Q4 2025.
  • A 5-year average of $13.1 million and a median of $5.1 million in 2021 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: rose 0.43% in 2023, then decreased 0.41% in 2024.
  • Bio-Rad Laboratories' Shares Outstanding stood at $5.1 million in 2021, then decreased by 0.08% to $5.1 million in 2022, then grew by 0.43% to $5.1 million in 2023, then dropped by 0.41% to $5.1 million in 2024, then decreased by 0.16% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Shares Outstanding are $5.1 million (Q4 2025), $5.1 million (Q4 2024), and $5.1 million (Q4 2023).